Intel shares fell 17% on Friday after the company posted a $333 million net loss for the final quarter and warned of a $0.21‑per‑share loss in Q1. Analysts blamed supply shortages from data‑center demand and a disappointing earnings outlook, prompting a sharp sell‑off that erased gains seen earlier in the week.

Abbott slid 13.8% last week after missing revenue estimates, with nutrition sales down 8.9% amid lower volumes and price moves aimed at future growth. The company’s guidance fell short of expectations, and analysts noted that the weaker Q4 diabetes numbers could weigh on the FY26 revenue outlook.

Qiagen rallied 13% after a Bloomberg report revealed the firm is exploring strategic options, including a potential sale, sparking renewed takeover interest. SanDisk added 11.4% to its recent gains, buoyed by sustained memory demand, while AMD and other chipmakers continue to benefit from AI‑driven server CPU demand.

Investors will monitor Intel’s revised guidance and Abbott’s nutrition strategy as key indicators of broader tech and healthcare resilience. Meanwhile, Qiagen’s potential sale and the memory‑chip rally could reshape capital flows in the semiconductor sector, especially as AI workloads keep demand high.